These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 20814238)
1. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238 [TBL] [Abstract][Full Text] [Related]
2. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Ng CP; Bonavida B Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428 [TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy. Vallo S; Stege H; Berg M; Michaelis M; Winkelmann R; Rothweiler F; Cinatl J Oncol Rep; 2020 Apr; 43(4):1331-1337. PubMed ID: 32020226 [TBL] [Abstract][Full Text] [Related]
4. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080 [TBL] [Abstract][Full Text] [Related]
5. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Griffith TS; Kucaba TA; O'Donnell MA; Burns J; Benetatos C; McKinlay MA; Condon S; Chunduru S Apoptosis; 2011 Jan; 16(1):13-26. PubMed ID: 20734142 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Gillissen B; Richter A; Richter A; Overkamp T; Essmann F; Hemmati PG; Preissner R; Belka C; Daniel PT Cell Death Dis; 2013 May; 4(5):e643. PubMed ID: 23703388 [TBL] [Abstract][Full Text] [Related]
7. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686 [TBL] [Abstract][Full Text] [Related]
8. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169 [TBL] [Abstract][Full Text] [Related]
9. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Bockbrader KM; Tan M; Sun Y Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155 [TBL] [Abstract][Full Text] [Related]
10. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Hörnle M; Peters N; Thayaparasingham B; Vörsmann H; Kashkar H; Kulms D Oncogene; 2011 Feb; 30(5):575-87. PubMed ID: 20856198 [TBL] [Abstract][Full Text] [Related]
11. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells. Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560 [TBL] [Abstract][Full Text] [Related]
12. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553 [TBL] [Abstract][Full Text] [Related]
13. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673 [TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Sinicrope FA; Penington RC; Tang XM Clin Cancer Res; 2004 Dec; 10(24):8284-92. PubMed ID: 15623604 [TBL] [Abstract][Full Text] [Related]
16. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma. Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656 [TBL] [Abstract][Full Text] [Related]
17. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366 [TBL] [Abstract][Full Text] [Related]
18. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974 [TBL] [Abstract][Full Text] [Related]
19. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. Roa WH; Chen H; Fulton D; Gulavita S; Shaw A; Th'ng J; Farr-Jones M; Moore R; Petruk K Clin Invest Med; 2003 Oct; 26(5):231-42. PubMed ID: 14596484 [TBL] [Abstract][Full Text] [Related]
20. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]